Research and Markets has announced the addition of the "Osteoarthritis - Pipeline Review, H2 2016" report to their offering.
'Osteoarthritis - Pipeline Review, H2 2016'; Osteoarthritis pipeline therapeutics constitutes close to 110 molecules. Out of which approximately 98 molecules are developed by Companies and remaining by the Universities Institutes.
Furthermore, the publisher says; Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like nonsteroidal anti-inflammatory drugs (NSAIDs) and exercise.
The report 'Osteoarthritis - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Osteoarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 18, 17, 43 and 13 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 6 molecules, respectively.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/wnzpzn/osteoarthritis
View source version on businesswire.com: http://www.businesswire.com/news/home/20160928005746/en/Business Wire
Last updated on: 28/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.